Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 28, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Tissue-based molecular markers for renal cell carcinoma.

M Rink1, F K H Chun, B Robinson

  • 1Department of Urology, University of Hamburg, Hamburg, Germany.

Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology
|October 15, 2011
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Stereotactic Ablative Body Radiotherapy for Renal Cell Carcinoma With Thrombus: Do or Do Not?

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

["Connected device for monitoring patients treated by prostatectomy: Implementation and qualitative assessment"].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same author

Work-related injuries and attendance at a Canadian regional emergency department.

Occupational medicine (Oxford, England)·2023
Same author

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

The NeuroSAFE frozen section technique during radical prostatectomy - Implementation and optimization of technical aspects in a routine pathology workflow.

Pathology, research and practice·2023
Same author

Pediatric Cardiology Fellowship Standards for Training in Exercise Medicine and Curriculum Outline.

Pediatric cardiology·2022

Molecular markers show promise for personalizing renal cell carcinoma (RCC) treatment and risk stratification. However, current markers lack specificity, necessitating novel biomarkers for improved clinical decision-making in RCC.

Area of Science:

  • Urology
  • Oncology
  • Molecular Biology

Background:

  • Targeted therapies have advanced renal cell carcinoma (RCC) treatment, enabling personalized approaches.
  • Molecular markers are crucial for accurate risk stratification and treatment planning in RCC.
  • The heterogeneity of renal masses necessitates precise diagnostic and prognostic tools.

Purpose of the Study:

  • To review current molecular markers for renal cell carcinoma (RCC).
  • To elucidate the clinical impact and future perspectives of these markers.
  • To identify the need for novel biomarkers in RCC management.

Main Methods:

  • A comprehensive English-language literature review was conducted.
  • The Medline database was searched for studies published between 1990 and September 2010.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Experiment Videos

Last Updated: May 28, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

  • Focus was placed on tissue-based molecular markers and their association with RCC.

    • Main Results:

    • Numerous molecular markers (e.g., HIF-α, VEGF, CAIX, mTOR, survivin) have been investigated in RCC.
    • While some markers show potential, limited specificity and predictive accuracy hinder daily clinical use.
    • Tumor histology variability further complicates the utility of existing molecular markers.

    Conclusions:

    • Novel molecular markers are urgently needed for accurate histologic and biologic classification of RCC.
    • A panel of molecular markers is likely to guide clinical decisions in the future.
    • Systematic discovery, verification, and validation efforts are essential to advance RCC molecular marker research.